Diagnostic accuracy of first‐trimester combined screening for early‐onset and preterm pre‐eclampsia at 8–10 compared with 11–13 weeks' gestation
Open Access
- 10 May 2020
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 57 (1) , 84-90
Abstract
Objectives: To compare the ability of first‐trimester combined screening for pre‐eclampsia (PE) to predict early‐onset and preterm PE when pregnancy‐associated plasma protein‐A (PAPP‐A) and placental growth factor (PlGF) were assessed before vs after 11 weeks' gestation.Methods: This was a secondary analysis of a prospective cohort study of singleton pregnancies undergoing routine first‐trimester screening conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between October 2015 and September 2017. Demographic characteristics, obstetric history, maternal history and biophysical markers (mean uterine artery pulsatility index and mean arterial blood pressure (MAP)) were recorded at the first‐trimester scan (at 11 + 0 to 13 + 6 weeks' gestation). Maternal serum concentrations of PAPP‐A and PlGF were assessed from the routine first‐trimester blood test (at 8 + 0 to 13 + 6 weeks). Women were classified into two groups depending on whether serum biomarkers were assessed at 8 + 0 to 10 + 6 weeks or at 11 + 0 to 13 + 6 weeks. Probability scores for early‐onset and preterm PE were calculated by using two different algorithms: the multivariate Gaussian‐distribution model and The Fetal Medicine Foundation (FMF) competing‐risks model. Receiver‐operating‐characteristics (ROC) curves were produced and detection rates at fixed 5% and 10% false‐positive rates were computed to compare the performance of these algorithms when PAPP‐A and PlGF were assessed before vs after 11 weeks.Results: Of the 2641 women included, serum biomarkers were assessed before 11 weeks in 1675 (63.4%) and at or after 11 weeks in 966 (36.6%). Of these, 90 (3.4%) women developed PE, including 11 (0.4%) cases of early‐onset PE and 30 (1.1%) of preterm PE. Five (45.5%) cases of early‐onset and 16 (53.3%) of preterm PE were identified in the group in which serum biomarkers were assessed at 8 + 0 to 10 + 6 weeks and six (54.5%) cases of early‐onset and 14 (46.7%) of preterm PE in the group in which serum biomarkers were assessed at 11 + 0 to 13 + 6 weeks. In the prediction of early‐onset and preterm PE using the Gaussian algorithm, no differences were observed between the areas under the ROC curves (AUCs) when PAPP‐A and PlGF were measured before or after 11 weeks. In the prediction of early‐onset and preterm PE using the FMF algorithm, no differences were observed between AUCs for any of the combinations used for risk calculation when the serum biomarkers were obtained before vs after 11 weeks, except for the combination of PAPP‐A and MAP, which showed a greater AUC for the prediction of early‐onset PE when PAPP‐A was measured at or after 11 weeks.Conclusions: The prediction of early‐onset and preterm PE is similar when serum biomarkers are measured before or after 11 weeks. This allows the use of a two‐step approach for PE risk assessment that permits immediate risk calculation at the time of the first‐trimester scan. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.Keywords
This publication has 16 references indexed in Scilit:
- A new model for screening for early-onset preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2020
- Aspirin versus Placebo in Pregnancies at High Risk for Preterm PreeclampsiaNew England Journal of Medicine, 2017
- Importance of Timing First-Trimester Placental Growth Factor and Use of Serial First-Trimester Placental Growth Factor Measurements in Screening for PreeclampsiaFetal Diagnosis and Therapy, 2017
- Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical MarkersFetal Diagnosis and Therapy, 2012
- Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–8: a reviewBritish Journal of Anaesthesia, 2011
- First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationUltrasound in Obstetrics & Gynecology, 2010
- Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsiaClinical Biochemistry, 2010
- The Global Impact of Pre-eclampsia and EclampsiaSeminars in Perinatology, 2009
- First‐trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional studyPrenatal Diagnosis, 2004
- Critical care in obstetrical patients: an eight-year review.1997